A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease.

[1]  M. Suarez‐Almazor,et al.  Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases , 2023, Oncoimmunology.

[2]  I. Kister,et al.  Immune Checkpoint Inhibitors in Patients with Pre-existing Neurologic Autoimmune Disorders , 2023, Current Neurology and Neuroscience Reports.

[3]  Shenmin Zhang,et al.  Pre-Existing Inflammatory Disease Predicts Cutaneous Immunotherapy Toxicity Development: A Multi-Institutional Cohort Study , 2023, medRxiv.

[4]  C. Cauquil,et al.  Tolerability of immune checkpoint inhibitors in patients with cancer and pre-existing multiple sclerosis. , 2023, European journal of cancer.

[5]  M. Hudson,et al.  AB1768-HPR SAFETY AND EFFICACY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH RHEUMATIC AUTOIMMUNE DISEASE: EXPERIENCE FROM THE CANADIAN RESEARCH GROUP OF RHEUMATOLOGY IN IMMUNO-ONCOLOGY (CANRIO) , 2023, Annals of the Rheumatic Diseases.

[6]  N. Seetharamu,et al.  Safety and Efficacy of Immune Checkpoint Inhibitors in Cancer Patients and Preexisting Autoimmune Disease: A Systematic Review and Meta-Analysis in Non-Small-Cell Lung Cancer. , 2023, Clinical lung cancer.

[7]  N. Shadick,et al.  Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study. , 2023, The Lancet. Rheumatology.

[8]  Jianbo Wang,et al.  Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases , 2023, Journal of Cancer Research and Clinical Oncology.

[9]  M. Ramos,et al.  Impact of Immune-Related Adverse Events on Immune Checkpoint Inhibitors Treated Cancer Patients’ Survival: Single Center Experience and Literature Review , 2023, Cancers.

[10]  Peng Chen,et al.  Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis , 2022, Human vaccines & immunotherapeutics.

[11]  R. Sullivan,et al.  Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy , 2022, JACC. CardioOncology.

[12]  R. Ishizawar,et al.  Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy , 2022, BMC Rheumatology.

[13]  T. Pham,et al.  Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study , 2022, RMD Open.

[14]  P. Lafforgue,et al.  Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer. , 2022, Joint bone spine.

[15]  M. Gönen,et al.  Association Between Toxic Effects and Survival in Patients With Cancer and Autoimmune Disease Treated With Checkpoint Inhibitor Immunotherapy. , 2022, JAMA oncology.

[16]  J. Grob,et al.  Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case–control study , 2022, Annals of the Rheumatic Diseases.

[17]  Andrew Snavely,et al.  Immune checkpoint inhibition in patients with inactive pre-existing neuromuscular autoimmune diseases , 2022, Journal of the Neurological Sciences.

[18]  Samuel J. S. Rubin,et al.  Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy , 2022, World journal of clinical cases.

[19]  N. Steele,et al.  Pembrolizumab for advanced non-small cell lung cancer (NSCLC): Impact of autoimmune comorbidity and outcomes following treatment completion , 2022, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[20]  Xiaoyan Liu,et al.  Risk factors for immune-related adverse events: what have we learned and what lies ahead? , 2021, Biomarker Research.

[21]  Sophia C Weinmann,et al.  Checkpoint Inhibitors in Melanoma Patients with Underlying Autoimmune Disease , 2021, Cancer management and research.

[22]  O. Lambotte,et al.  Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study. , 2021, European journal of cancer.

[23]  I. Osman,et al.  Preexisting immune‐mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors , 2021, Cancer medicine.

[24]  D. Daoussis,et al.  Should we be Afraid of Immune Check Point Inhibitors in Cancer Patients with Pre-Existing Rheumatic Diseases? Immunotherapy in Pre-Existing Rheumatic Diseases , 2021, Mediterranean journal of rheumatology.

[25]  D. Pardi,et al.  Letter: safety of immune checkpoint inhibitors in patients with pre‐established microscopic colitis—a single‐centre experience , 2021, Alimentary pharmacology & therapeutics.

[26]  K. Syrigos,et al.  Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group , 2021, Cancer Immunology, Immunotherapy.

[27]  W. Hopman,et al.  Safety and Clinical Outcomes of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Diseases , 2021, Journal of immunotherapy.

[28]  A. Cole,et al.  Risk of Immune-related Adverse Events in Melanoma Patients With Preexisting Autoimmune Disease Treated With Immune Checkpoint Inhibitors , 2021, American journal of clinical oncology.

[29]  A. Yamaguchi,et al.  Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysis , 2021, Supportive Care in Cancer.

[30]  Douglas B. Johnson,et al.  Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders , 2021, Journal for ImmunoTherapy of Cancer.

[31]  C. Schumann,et al.  Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada. , 2021, Lung cancer.

[32]  Namrata Singh,et al.  Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease , 2021, Annals of translational medicine.

[33]  T. Holderried,et al.  Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis , 2021, Therapeutic advances in musculoskeletal disease.

[34]  Vineel Bhatlapenumarthi,et al.  Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience , 2021, Journal of Cancer Research and Clinical Oncology.

[35]  Xianhe Xie,et al.  The safety and efficacy of immune-checkpoint inhibitors in patients with cancer and pre-existing autoimmune diseases. , 2021, Immunotherapy.

[36]  M. Forster,et al.  31P Safety and efficacy of immune checkpoint inhibitors in cancer patients with pre-existing autoimmune disease: A UK tertiary cancer centre experience , 2021 .

[37]  K. Syrigos,et al.  Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer , 2021, Journal for ImmunoTherapy of Cancer.

[38]  M. Suarez‐Almazor,et al.  Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis. , 2021, Immunotherapy.

[39]  Hui Tang,et al.  The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease , 2021, Frontiers in Oncology.

[40]  O. Dekkers,et al.  Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease , 2021, Annals of Internal Medicine.

[41]  G. Trifirò,et al.  Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors , 2021, Dermatologic therapy.

[42]  B. Halmos,et al.  Spectrum of PD-1 and PD-L1 inhibitor cutaneous adverse events in skin of color: a retrospective, single-institutional study in an urban community , 2021, Acta oncologica.

[43]  M. Hudson,et al.  Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology , 2021, Cancer Immunology, Immunotherapy.

[44]  J. Baehring,et al.  Neurotoxicities associated with immune checkpoint inhibitor therapy , 2021, Journal of Neuro-Oncology.

[45]  Hongyang Lu,et al.  Immune Checkpoint Inhibitors in Special Populations , 2021, Technology in cancer research & treatment.

[46]  Siddharth Singh,et al.  Systematic review with meta‐analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre‐existing inflammatory bowel diseases , 2020, Alimentary pharmacology & therapeutics.

[47]  A. Maraveyas,et al.  60P Real-world experience of immunotherapy in elderly cancer patients in a UK cancer centre , 2020 .

[48]  M. Suarez‐Almazor,et al.  658 Toxicities of single agent and combination immune checkpoint inhibitors in patients with pre-existing autoimmune diseases , 2020, Journal for ImmunoTherapy of Cancer.

[49]  M. Khattak,et al.  350P Rheumatologic immune related adverse events (irAEs) secondary to immune checkpoint inhibitor (ICI) therapy: A Western Australia experience , 2020 .

[50]  A. Aydıner,et al.  Nivolumab treatment for metastatic thymic epithelial tumors , 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[51]  S. Novello,et al.  Exploring the immune-checkpoint inhibitors’ efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease , 2020, Translational lung cancer research.

[52]  Zhuoli Zhang,et al.  Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies. , 2020, Autoimmunity reviews.

[53]  C. Schumann,et al.  Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP). , 2020, Lung cancer.

[54]  K. Thavorn,et al.  An evaluation of DistillerSR’s machine learning-based prioritization tool for title/abstract screening – impact on reviewer-relevant outcomes , 2020, BMC Medical Research Methodology.

[55]  R. Tothill,et al.  Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma , 2020, Journal for ImmunoTherapy of Cancer.

[56]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2020, BMJ.

[57]  R. Huddart,et al.  Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma. , 2020, European journal of cancer.

[58]  M. González-Gay,et al.  Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: a 3-year study of 102 cases from a single centre. , 2020, Clinical and experimental rheumatology.

[59]  C. Klein,et al.  Neurologic autoimmunity and immune checkpoint inhibitors , 2020, Neurology.

[60]  P. Khong,et al.  Low‐dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource‐constrained setting , 2020, Hematological oncology.

[61]  S. Rakshit,et al.  Immunotherapy in patients with autoimmune disease , 2020, Journal of thoracic disease.

[62]  H. Ogata,et al.  Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis , 2020, Digestive Diseases and Sciences.

[63]  V. Calvo,et al.  Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data , 2020, Lung cancer management.

[64]  E. Loftus,et al.  Use of immune checkpoint inhibitors in patients with pre-established inflammatory bowel diseases: retrospective case series. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[65]  M. Suarez‐Almazor,et al.  SAT0536 IMMUNE CHECKPOINT INHIBITOR THERAPY IN PATIENTS WITH PREEXISTING SARCOIDOSIS , 2020, Annals of the Rheumatic Diseases.

[66]  M. Merl,et al.  The impact of corticosteroid use during anti-PD1 treatment , 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[67]  Vineel Bhatlapenumarthi,et al.  Immune related adverse effects (IRAEs) in patients with cancer who received immune checkpoint inhibitors (ICIs): A single center experience from rural Maine. , 2020 .

[68]  S. Zhao,et al.  Real-world outcomes of immune-related adverse events in 2,125 patients managed with immunotherapy: A United Kingdom multicenter series. , 2020 .

[69]  A. Giobbie-Hurder,et al.  Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis. , 2020, JCO oncology practice.

[70]  T. Berghmans,et al.  Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders , 2020, Frontiers in Medicine.

[71]  A. Giobbie-Hurder,et al.  Su1189 SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH PREEXISTING INFLAMMATORY BOWEL DISEASE AND MICROSCOPIC COLITIS , 2020, Gastroenterology.

[72]  J. Larkin,et al.  Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  A. Peri,et al.  Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders. , 2020, The oncologist.

[74]  N. Ohmiya,et al.  Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody , 2020, BMC Cancer.

[75]  E. Lam,et al.  Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study , 2020, Journal for ImmunoTherapy of Cancer.

[76]  A. Pavlick,et al.  Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis , 2020, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[77]  A. Kotwal,et al.  PD-L1 Inhibitor-Induced Thyroiditis is Associated with Better Overall Survival in Cancer Patients. , 2019, Thyroid : official journal of the American Thyroid Association.

[78]  Douglas B. Johnson,et al.  Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  Raquel Sweezie,et al.  A Clinical Profile of Patients on Immune Checkpoint Inhibitors Referred to Rheumatology , 2019, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[80]  M. Suarez‐Almazor,et al.  Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature , 2019, Journal of Immunotherapy for Cancer.

[81]  F. Aubin,et al.  Vitiligo under anti-PD1 therapy is associated with increased survival in melanoma patients. , 2019, Journal of the American Academy of Dermatology.

[82]  W. Siu,et al.  Clinical outcome and toxicity for immunotherapy treatment in metastatic cancer patients. , 2019, Annals of palliative medicine.

[83]  D. Schadendorf,et al.  Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). , 2019, European journal of cancer.

[84]  L. Misery,et al.  Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study , 2019, Arthritis & rheumatology.

[85]  Namrata Singh,et al.  Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors , 2019, Medicine.

[86]  T. Taguchi,et al.  Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies , 2019, Clinical and Translational Oncology.

[87]  V. Velcheti,et al.  P2.04-48 Use of Immune Checkpoint Inhibitors in Patients with Advanced Lung Cancer and Pre-Existing Autoimmune Diseases , 2019, Journal of Thoracic Oncology.

[88]  R. Huddart,et al.  Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma , 2019, Annals of Oncology.

[89]  O. Ukimura,et al.  Safety of PD-1/PD-L1 blockade in patients with preexisting positive antinuclear antibodies and autoimmune disease , 2019, Annals of Oncology.

[90]  M. Galeazzi,et al.  Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. , 2019, Autoimmunity reviews.

[91]  T. Powles,et al.  Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. , 2019, European urology.

[92]  S. Yeung,et al.  Safety of immune checkpoint blockade in patients with cancer and preexisting autoimmune diseases and/or chronic inflammatory disorders , 2019, Journal of Immunotherapy and Precision Oncology.

[93]  R. Sullivan,et al.  Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience. , 2019, Seminars in arthritis and rheumatism.

[94]  P. Grivas,et al.  Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[95]  M. Hudson,et al.  SAT0598 RHEUMATIC IMMUNE RELATED ADVERSE EVENTS ASSOCIATED WITH CANCER IMMUNOTHERAPY: A NATIONWIDE MULTI-CENTER CANADIAN COHORT FROM THE CANADIAN RESEARCH GROUP OF RHEUMATOLOGY IN IMMUNO-ONCOLOGY (CANRIO) , 2019 .

[96]  Ami A. Shah,et al.  A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[97]  T. Choueiri,et al.  Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC). , 2019, Journal of Clinical Oncology.

[98]  S. Sandigursky,et al.  Toxicities of single agent and combination immune checkpoint inhibitors in patients with autoimmune diseases. , 2019, Journal of Clinical Oncology.

[99]  W. Rubinstein,et al.  Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs). , 2019, Journal of Clinical Oncology.

[100]  E. Lipson,et al.  Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. , 2019, The oncologist.

[101]  C. Crowson,et al.  Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single‐Center Cohort of Sixty‐One Patients , 2019, Arthritis & rheumatology.

[102]  N. Tinari,et al.  Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. , 2019, The oncologist.

[103]  J. Villano,et al.  Multiple sclerosis outcomes after cancer immunotherapy , 2019, Clinical and Translational Oncology.

[104]  B. Solomon,et al.  Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. , 2018, European journal of cancer.

[105]  D. Schadendorf,et al.  Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[106]  Y. Ohe,et al.  Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab , 2018, Cancer science.

[107]  A. Kartolo,et al.  Predictors of immunotherapy-induced immune-related adverse events. , 2018, Current Oncology.

[108]  D. Rubin,et al.  Safety of Immune Checkpoint Inhibitors for Cancer Therapy in IBD Patients , 2018, American Journal of Gastroenterology.

[109]  K. Ohe,et al.  Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma , 2018, BMC Endocrine Disorders.

[110]  J. Riess,et al.  Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. , 2018, Journal of Clinical Oncology.

[111]  F. Guaraldi,et al.  Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution , 2018, Journal of Endocrinological Investigation.

[112]  R. Board,et al.  Real-world experience with pembrolizumab toxicities in advanced melanoma patients: a single-center experience in the UK , 2018, Melanoma management.

[113]  Douglas B. Johnson,et al.  Immune Checkpoint Inhibitor Therapy in Patients With Autoimmune Disease. , 2018, Oncology.

[114]  S. Markovic,et al.  Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience , 2018, Arthritis & rheumatology.

[115]  N. Girard,et al.  Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. , 2018, European journal of cancer.

[116]  J. Schachter,et al.  Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. , 2018, Autoimmunity reviews.

[117]  A. Gesierich,et al.  Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders , 2018, Cancer Immunology, Immunotherapy.

[118]  M. Akiyama,et al.  Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study , 2018, Journal of the Endocrine Society.

[119]  M. Suarez‐Almazor,et al.  Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease , 2018, Annals of Internal Medicine.

[120]  Matthew D. Hellmann,et al.  Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade , 2018, The New England journal of medicine.

[121]  A. Ravaud,et al.  Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort study , 2017, Annals of the rheumatic diseases.

[122]  G. Quéré,et al.  Safety of immune checkpoint inhibitors for the treatment of melanoma, bronchopulmonary and urologic neoplasms in patients with preexisting autoimmune disease , 2017 .

[123]  Ami A. Shah,et al.  Rheumatic and Musculoskeletal Immune‐Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature , 2017, Arthritis care & research.

[124]  A. Ribas,et al.  Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) , 2017, The Lancet.

[125]  R. Pazdur,et al.  FDA analysis of patients with baseline autoimmune diseases treated with PD-1/PD-L1 immunotherapy agents. , 2017 .

[126]  A. Gesierich,et al.  Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. , 2017, European journal of cancer.

[127]  M. Donia,et al.  Cancer immunotherapy in patients with preexisting autoimmune disorders , 2017, Seminars in Immunopathology.

[128]  V. Velcheti,et al.  Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity , 2017, RMD Open.

[129]  X. Mariette,et al.  Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy , 2017, Annals of the rheumatic diseases.

[130]  R. Sullivan,et al.  Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[131]  J. Naidoo,et al.  Immune‐Related Adverse Events From Immune Checkpoint Inhibitors , 2016, Clinical pharmacology and therapeutics.

[132]  G. McArthur,et al.  The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[133]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[134]  R. Sullivan,et al.  Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. , 2016, JAMA oncology.

[135]  A. Lerner,et al.  The World Incidence and Prevalence of Autoimmune Diseases is Increasing , 2015 .

[136]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[137]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[138]  J. Slansky,et al.  Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. , 2012, Anticancer research.

[139]  A. Stang.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses , 2010, European Journal of Epidemiology.

[140]  Glinda S Cooper,et al.  Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. , 2009, Journal of autoimmunity.

[141]  S. Hogan,et al.  Environmental epidemiology and risk factors for autoimmune disease , 2003, Current opinion in rheumatology.

[142]  OUP accepted manuscript , 2022, Journal of the National Cancer Institute.